According to a study in Obstetrics & Gynecology journal, the women who used elagolix for the treatment of pain concerning endometriosis had clinically significant health-related quality of life (HRQOL) improvements.

This study assessed the effects of elagolix on health-related quality of life (HRQOL) evaluated with the help of EHP-30 (Endometriosis Health Profile-30).

The study population who used elagolix for moderate to severe pain relief due to endometriosis was divided into 3 groups as: placebo, elagolix 150 mg once a day, or elagolix 200 mg twice a day. At the starting, the patients were given the EHP-30 questionnaire, and at months 1, 3, and 6 of therapy. Earlier recognized responder definitions were used to decide the proportion of patients with clinically meaningful EHP-30 parameters.

At month 6, the likelihoods of achieving EHP-30 subscale responder definitions for pain, control and powerlessness, self-image, social support, and emotional well-being were 169%, 129%, 80%, 70%, and 67% more, correspondingly, in the 200-mg group, as compared to with placebo. 

The 150-mg group also had higher likelihoods of achieving responder definitions as compared to placebo for all subscales but with lower magnitude than the 200-mg dose of elagolix. Details mentioned in the following table 1:

Table 1: Increased probability of fulfilling the pain subscale responder definition at month 6 for 200 mg and 150 mg doses of elagolix